This study evaluated the attitudes, knowledge, and educational experiences of psychiatry residents regarding psychedelics and psychedelic-assisted therapy (PAT). In 2023, we distributed an anonymous survey to United States psychiatry residents, assessing demographics, knowledge, and opinions on psychedelics/PAT. The survey also included items asking respondents to retrospectively self-report...
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...
Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually...